This technology includes Streptococcus pneumoniae isolates collected through CDC’s Global Strain Bank project with particular serotypes. They were collected as part of routine clinical and surveillance activities and have a wide variety of uses including research, diagnostic, and the development of therapeutics.
This technology includes eight mouse monoclonal antibodies (mAb) and their corresponding hybridomas used for the Enzyme Linked Immunosorbent Assay (ELISA) detection and identification of Marburg (3) and Lassa (5) virus antigens. Lateral flow assays for hemorrhagic fevers are being developed in response to the Ebola outbreak. Our cocktail can identify different proteins for each virus; Marburg viral proteins 35 and 40 (VP35, VP40) and Lassa nucleoprotein (NP) and glycoprotein (G2). All known Marburg and Lassa viruses can be captured in the ELISA assay.
This technology includes an optimized influenza A/H5 subtyping real-time RT-PCR assay for detection and characterization of Asian lineage A/H5N1 viruses. The highly pathogenic avian influenza (HPAI) A/H5N1 viruses, first isolated in human in 1997, have spread among birds over seventy countries on three continents. In 2014 a novel reassortant HPAI A/H5N8 virus has been detected in poultry in Asia, Europe, As well as Canada and USA. In addition, genetic reassortment of this virus with circulating avian influenza viruses has resulted in the novel viral combinations.
This technology includes HIV clones to develop proteomic microarrays for HIV research. The microarray chip can be used to monitor the antibody response to all proteins and many epitopes of HIV-1.
This technology includes Klebsiella pneumoniae isolate to be used for research studies and diagnostic tests to detect antimicrobial resistance.
This technology includes an Escherichia coli isolate to be used in for research purposes and the development of diagnostics. The isolate is unique because it has the mcr-1 gene.
This technology includes an isolate of the yeast species Candida auris to be used in the development of diagnostic tools or anti-fungal for therapeutic use.
This technology includes Borrelia hermsii isolate for diagnostic development of serologic tests. Borrelia hermsii is the major identified cause of Tick-Borne Relapsing Fever (TBRF) in humans in the western United States. Initial signs and symptoms of infection include fever, nausea, headache and malaise. Most cases are diagnosed on clinical suspicion and epidemiologic risk. Common source, case clusters notable. Microscopy and serologic detection of antibody responses to infection may aid in the laboratory confirmation or infection.
This technology includes natural Yellow Fever Virus, Zika Virus, and Powassan Virus isolates for various uses in research and development of diagnostics and immunizations.
This technology includes a murine IgG1 monoclonal antibody (mAb), 1C7, for the detection of Chaetomium globosum. The development of mAb-based detection methods may provide a standardized approach to quantify the target organism(s) using rapid immunoassay platforms. To date, mAbs are not available for Chaetomium species. C. globosum enolase was selected as a candidate biomarker for the detection of this species due to its presence within the cytosol and cell wall. C. globosum enolase was cloned and a recombinant expressed in Escherichia coli for the production of mAbs.